Literature DB >> 12084224

Immune gene therapy in urology.

Ingo Kausch1, Peter Ardelt, Andreas Böhle, Timothy L Ratliff.   

Abstract

Effective treatments are needed urgently for metastatic disease in bladder, prostate, and renal cell cancer. In the past few years, several new approaches for treating these conditions have been proposed, including gene therapy. A number of different strategies have been developed to accomplish urologic cancer gene therapy. Genetic immunomodulation strategies attempt to activate immune defense mechanisms against tumor cells by transfer of tumor antigens, cytokine genes, or strongly immunogenic cell surface molecules. In this review, we illustrate the recent developments in immune gene therapy.

Entities:  

Mesh:

Year:  2002        PMID: 12084224     DOI: 10.1007/s11934-002-0015-6

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  41 in total

1.  Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells.

Authors:  L Höltl; C Rieser; C Papesh; R Ramoner; M Herold; H Klocker; C Radmayr; A Stenzl; G Bartsch; M Thurnher
Journal:  J Urol       Date:  1999-03       Impact factor: 7.450

2.  Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model.

Authors:  Y Nasu; C H Bangma; G W Hull; H M Lee; J Hu; J Wang; M A McCurdy; S Shimura; G Yang; T L Timme; T C Thompson
Journal:  Gene Ther       Date:  1999-03       Impact factor: 5.250

Review 3.  Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing.

Authors:  S Radoja; A B Frey
Journal:  Mol Med       Date:  2000-06       Impact factor: 6.354

4.  The potent antitumor effects of combined p16 gene and GM-CSF gene therapy through efficient induction of antitumor immunity.

Authors:  L H Wang; D W Ju; Y Sun; Q Tao; S Qian; J Mi; H Hamada; X Cao
Journal:  J Cancer Res Clin Oncol       Date:  2001-02       Impact factor: 4.553

5.  Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model.

Authors:  Y Horiguchi; W A Larchian; R Kaplinsky; W R Fair; W D Heston
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

6.  Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.

Authors:  S E Lee; R J Jin; S G Lee; S J Yoon; M S Park; D S Heo; H Choi
Journal:  Anticancer Res       Date:  2000 Jan-Feb       Impact factor: 2.480

7.  Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.

Authors:  J Wang; S Saffold; X Cao; J Krauss; W Chen
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

Review 8.  Mechanisms of action and toxicity of immunotherapy with cytokines.

Authors:  J W Mier; M B Atkins
Journal:  Curr Opin Oncol       Date:  1993-11       Impact factor: 3.645

9.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.

Authors:  R Soiffer; T Lynch; M Mihm; K Jung; C Rhuda; J C Schmollinger; F S Hodi; L Liebster; P Lam; S Mentzer; S Singer; K K Tanabe; A B Cosimi; R Duda; A Sober; A Bhan; J Daley; D Neuberg; G Parry; J Rokovich; L Richards; J Drayer; A Berns; S Clift; L K Cohen; R C Mulligan; G Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

10.  Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo.

Authors:  P Jantzer; D J Schendel
Journal:  Cancer Res       Date:  1998-07-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.